Improvements in breast cancer survival over time, related to adjuvant treatment and node status
Introduction
Breast cancer survival is improving1 and studies have shown that use of adjuvant treatment is one of the main reasons. Chemotherapeutic drugs have become increasingly effective over the past decades and have produced a significant reduction in breast cancer mortality rates.2, 3 This, in turn, has led to a general rise in the use of systemic adjuvant therapies.4 But, depending on stage of the disease and tumour characteristics, there has been debate about the indications for and absolute benefit from adjuvant treatment in different prognostic groups.
The present study examined two groups of patients, those who were node negative and those who were node positive at the time of diagnosis. The aim was to compare the use of adjuvant therapy between two time periods and to relate changes to differences in breast cancer recurrence and survival.
Section snippets
Patient selection
The study was a review of breast cancer patients diagnosed between 1980 and 2002. Patient details were collected prospectively on an actively managed database and the follow-up is near-complete. Only patients with operable breast cancer were included in the study and those who had no node status recorded, solely in situ carcinoma or bilateral disease were excluded.
Tumour characteristics and adjuvant treatment
The remaining 1517 patients were divided into two groups according to the nodal status at the time of diagnosis. The following data
Overall survival improvement
There was a significant improvement in RFS and BCSS when comparing the two time periods 1980–1995 and 1996–2002. RFS increased from 76% to 85% (HR 1.63, 95% CI 1.32–2.01, p < 0.01), and BCSS from 84% to 90% (HR 1.4, 95% CI 1.1–1.82, p < 0.01). Use of adjuvant therapy was significantly increased during the latter period, in both node positive and node negative patients including prognostic subgroups (Table 1). In Cox regression analysis the use of adjuvant radiotherapy and endocrine therapy were
Adjuvant treatment and survival in node positive patients
The present study shows that breast cancer recurrence rates and survival have significantly improved over time, correlating with a general increase in the use of adjuvant treatment in all prognostic groups. The importance of the increasing use of adjuvant radiotherapy and endocrine therapy on RFS in the second time period was confirmed in a multivariate analysis. The increased use of adjuvant chemotherapy did not show a significant improvement in the outcome although there was a switch from CMF
Conclusion
Adjuvant treatment is effective in reducing recurrence and mortality in node positive breast cancer patients and in node negative patients with larger tumours. The outcome in node negative patients with low grade and small-sized tumours is very good and it is difficult to improve on an already good prognosis in this patient group.
Conflict of interest
There were no conflicts of interests.
References (18)
- et al.
UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years
Lancet
(2000) - et al.
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer
Clin Breast Cancer
(2001) - et al.
The international (Ludwig) breast cancer study group trials I–IV: 15 years follow-up
Ann Oncol
(1994) - et al.
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials
Lancet
(2004) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Lancet
(2005)Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Lancet
(2005)- et al.
Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999
J Natl Cancer Inst
(2002) - et al.
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up
N Engl J Med
(1995) - et al.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
JAMA
(2006)
Cited by (9)
Development and implementation of a population-based breast cancer quality index in Queensland, Australia
2021, Journal of Cancer PolicyCitation Excerpt :While it could be argued the changes may reflect variation in patient population over time, we did not observe any change in BCS rate nor in the distribution of clinical factors over time. We observed an increase in the use of adjuvant intravenous systemic therapy for women 70 years or less with positive lymph nodes, similar to others [30,31]. A significant increase in the number of patients being discussed at MDTs over time was also observed.
Comparison of hepatic resection and systemic treatment of breast cancer liver metastases: A propensity score matching study
2020, American Journal of SurgeryCitation Excerpt :While the total DCR was 60.4% and the overall response rate was 32.0%, the median IHPFS was only 7.5 months and the 1-, 3- and 5-year IHPFS rates were 32.1%, 7.4% and 4.3%, respectively (Fig. 4, Table 3). Although the evolution of chemotherapeutic agents has resulted in improved survival for patients with metastatic disease,23 the potential cure of BCLM is rarely achieved by systemic chemotherapy alone. Furthermore, compromised liver function modifies the regimens and decreases doses of chemotherapy, which can limit its antitumor effectiveness.24,25
Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases
2021, World Journal of Surgical Oncology